Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 5.28%1.07M | -22.76%590.24K | -23.46%2.65M | -19.76%579.21K | -54.87%283.9K | 79.48%1.02M | -50.31%764.13K | -22.75%3.46M | -20.31%721.86K | -32.57%629.01K |
Operating revenue | 5.28%1.07M | -22.76%590.24K | -23.46%2.65M | -19.76%579.21K | -54.87%283.9K | 79.48%1.02M | -50.31%764.13K | -22.75%3.46M | -20.31%721.86K | -32.57%629.01K |
Cost of revenue | -7.92%747.67K | -22.64%497.39K | -22.87%2.13M | 20.76%562.06K | -78.08%117.76K | 71.60%811.96K | -50.23%642.96K | -27.28%2.77M | -39.80%465.44K | -33.72%537.26K |
Gross profit | 57.34%323.91K | -23.38%92.85K | -25.82%510.35K | -93.31%17.16K | 81.09%166.15K | 119.14%205.87K | -50.72%121.17K | 3.13%688K | 93.15%256.42K | -25.00%91.75K |
Operating expense | 64.04%1.27M | 90.71%1.06M | -14.33%2.85M | 30.07%750.93K | 5.79%766.51K | -28.37%774.7K | -40.96%555.16K | -48.25%3.32M | -53.50%577.33K | 16.82%724.56K |
Selling and administrative expenses | 58.58%1.23M | 89.16%1.05M | -14.14%2.83M | 28.55%742.17K | 4.54%756.12K | -27.85%774.7K | -39.62%555.16K | -48.16%3.29M | -53.43%577.33K | 16.62%723.27K |
-General and administrative expense | 58.58%1.23M | 89.16%1.05M | -14.14%2.83M | 28.55%742.17K | 4.54%756.12K | -27.85%774.7K | -39.62%555.16K | -48.16%3.29M | -53.43%577.33K | 16.62%723.27K |
Research and development costs | --42.32K | --8.62K | -36.02%19.15K | --8.76K | 705.58%10.39K | --0 | --0 | -56.30%29.94K | --0 | --1.29K |
Operating profit | -66.47%-946.93K | -122.56%-965.89K | 11.33%-2.34M | -128.66%-733.78K | 5.13%-600.37K | 42.40%-568.83K | 37.51%-433.99K | 54.20%-2.64M | 71.06%-320.91K | -27.10%-632.81K |
Net non-operating interest income expense | -289.40%-24.21K | -73.54%1.4K | 913.84%33.64K | 4.7K | 10.89K | 12.78K | 227.55%5.27K | 91.66%-4.13K | 0 | 0 |
Non-operating interest income | -97.35%339 | -73.54%1.4K | --33.64K | --4.7K | --10.89K | --12.78K | --5.27K | --0 | --0 | --0 |
Non-operating interest expense | --24.55K | ---- | --0 | --0 | --0 | --0 | ---- | -91.66%4.13K | --0 | --0 |
Other net income (expense) | ||||||||||
Income before tax | -74.65%-971.14K | -124.97%-964.49K | 12.75%-2.3M | -127.19%-729.08K | 6.85%-589.47K | 43.69%-556.04K | 38.63%-428.72K | 54.52%-2.64M | 71.53%-320.91K | -21.76%-632.81K |
Income tax | ||||||||||
Net income | -74.65%-971.14K | -124.97%-964.49K | 12.75%-2.3M | -127.19%-729.08K | 6.85%-589.47K | 43.69%-556.04K | 38.63%-428.72K | 54.52%-2.64M | 71.53%-320.91K | -21.76%-632.81K |
Net income continuous Operations | -74.65%-971.14K | -124.97%-964.49K | 12.75%-2.3M | -127.19%-729.08K | 6.85%-589.47K | 43.69%-556.04K | 38.63%-428.72K | 54.52%-2.64M | 71.53%-320.91K | -21.76%-632.81K |
Minority interest income | ||||||||||
Net income attributable to the parent company | -74.65%-971.14K | -124.97%-964.49K | 12.75%-2.3M | -127.19%-729.08K | 6.85%-589.47K | 43.69%-556.04K | 38.63%-428.72K | 54.52%-2.64M | 71.53%-320.91K | -21.76%-632.81K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -74.65%-971.14K | -124.97%-964.49K | 12.75%-2.3M | -127.19%-729.08K | 6.85%-589.47K | 43.69%-556.04K | 38.63%-428.72K | 54.52%-2.64M | 71.53%-320.91K | -21.76%-632.81K |
Basic earnings per share | -50.00%-0.03 | -200.00%-0.03 | 12.50%-0.07 | -100.00%-0.02 | 0.00%-0.02 | 33.33%-0.02 | 50.00%-0.01 | 71.43%-0.08 | 80.00%-0.01 | 33.33%-0.02 |
Diluted earnings per share | -50.00%-0.03 | -200.00%-0.03 | 12.50%-0.07 | -100.00%-0.02 | 0.00%-0.02 | 33.33%-0.02 | 50.00%-0.01 | 71.43%-0.08 | 80.00%-0.01 | 33.33%-0.02 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |